FENC
The PEDMARK train keeps rolling
Fennec Pharmaceuticals — the company you might still know as Adherex Technologies — just put up a pretty loud second quarter. Net product sales hit $17.1 million, which was up roughly 78% from $9.7 million a year ago. Not exactly a sleepy little update.
Why investors are paying attention
The star of the show is PEDMARK, and demand for it is still climbing. That matters because for biotech and specialty pharma names, revenue growth is the difference between "interesting story" and "actual business." When one product keeps gaining traction, the market starts wondering how much more runway is left.
The quick read
- Q2 2026 net product sales: $17.1 million
- Year-ago sales: $9.7 million
- Growth: about 78%
- Driver: rising demand for PEDMARK
Big picture
If sales keep compounding like this, Fennec looks less like a tiny one-product science project and more like a company building a real commercial base. Investors will be watching whether that momentum sticks — because in biotech, the market loves a growth story almost as much as it loves a drug with a good name.